With over 3.04 million Nutrien Ltd. (NTR) shares trading Tuesday and a closing price of $33.13 on the day, the dollar volume was approximately $100.87 million. The shares have shown a positive weekly performance of 0.55% and its price on 07/28/20 lost nearly -0.93%. Currently, there are 569.15M common shares owned by the public and among those 568.87M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 23 analysts who have offered their price forecasts for NTR have a consensus price objective of $44.59. The analysts have set the share’s price value over the next 12 months at a high of $62.00 and a low of $36.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Nutrien Ltd. stock is 2.10 for the next 12 months. But an upside of 46.56% will see the stock hit the forecast high price target while mean target price for the stock is $44.00.
The top 3 mutual fund holders in Nutrien Ltd. are First Eagle Global Fund, Caisse de Dépôt & Placement du Qu, and Dodge & Cox Funds – International. First Eagle Global Fund owns 11.28 million shares of the company’s stock, all valued at over $362.03 million. Caisse de Dépôt & Placement du Qu bought 1.25 million shares to see its total holdings expand to 10.84 million shares valued at over $347.98 million and representing 1.91% of the shares outstanding. Dodge & Cox Funds – International bought 0.7 million shares to bring its total holdings to over 10.43 million shares at a value of $334.95 million. Dodge & Cox Funds – International now owns shares totaling to 1.83% of the shares outstanding.
Shares of Nutrien Ltd. (NYSE: NTR) opened at $33.23, down -$0.21 from a prior closing price of $33.44. However, the script later closed the day at $33.13, down -0.93%. The company’s stock has a 5-day price change of 0.55% and -7.07% over the past three months. NTR shares are trading -30.85% year to date (YTD), with the 12-month market performance down to -34.45% lower. It has a 12-month low price of $23.85 and touched a high of $55.25 over the same period. Currently, 3.04 million shares have been traded, compared to an average intraday trading volume of 1.48 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.21%, -3.10%, and -17.32% respectively.
Institutional ownership of Nutrien Ltd. (NYSE: NTR) shares accounts for 67.92% of the company’s 569.15M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $18.86B. The stock’s trailing 12-month PE ratio is 20.82, while the earnings-per-share (ttm) stands at $1.59. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.26% over the week and 2.46% over the month.
Analysts forecast that Nutrien Ltd. (NTR) will achieve an EPS of $0.29 for the current quarter, $1.27 for the next quarter and $3.04 for 2019. The lowest estimate earnings-per-share for the quarter is $0.23 while analysts give the company a high EPS estimate of $0.33.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 23 brokerage firm advisors rate Nutrien Ltd. (NTR) as a “Moderate Buy” at a consensus score of 2.10. Specifically, 17 Wall Street analysts polled rate the stock as a buy, while 4 of the 23 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the NTR, a number of firms have released research notes about the stock. BofA Securities stated their Buy rating for the stock in a research note on July 13, 2020, with the firm’s price target at. Consumer Edge Research coverage for the Nutrien Ltd. (NTR) stock in a research note released on May 14, 2020 offered a Equal Weight rating with a price target of. BofA/Merrill was of a view on May 11, 2020 that the stock is Underperform, while Citigroup gave the stock Buy rating on April 09, 2020, issuing a price target of $31- $45. Goldman on their part issued Buy rating on March 26, 2020.